{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-389264","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-09-11T20:05:52+00:00","discovered_at":"2026-09-11T20:07:00.403988+00:00","generated_at":"2026-09-11T20:07:13.113396+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teva prices $4.9B senior notes to refinance higher-coupon debt","bullets":["EUR tranches: €1.0B 4.250% due 2033, €500M 4.625% due 2036.","USD tranches: $1.0B 5.500% due 2034, $1.0B 5.750% due 2037, $1.2B 5.250% due 2032.","Closing expected Sept 16, 2026; senior unsecured, guaranteed by Teva.","Proceeds fund redemptions: all 6.750% 2028, 7.875% 2029, 7.375% 2029, up to $450M 4.750% 2027, €1.25B 4.375% 2030 (reduced to €1.15B).","Also plans to redeem all 8.125% 2031 notes; remainder for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-389264","json":"https://secwatch.observer/filing/0001193125-26-389264.json","markdown":"https://secwatch.observer/filing/0001193125-26-389264.md","text":"https://secwatch.observer/filing/0001193125-26-389264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/0001193125-26-389264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-11T20:07:13.113396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}